SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Cipla - Quaterly Results

24 Jul 2026 Evaluate
The company's total revenue for the quarter ended June 2026 saw a slight change in the total revenue, having registered a total revenue of Rs. 50776.80 millions.Net profit of the cmpany stood at Rs. 8621.60 millions for the quarter ended June 2026 a decline of -33.84% from Rs. 13031.30 millions  in the same quarter last year.Operating Profit reported a sharp decline to 13286.90 millions from 18955.20 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202606 202506 % Var 202606 202506 % Var 202603 202503 % Var
Sales 50776.80 50461.70 0.62 50776.80 50461.70 0.62 189799.50 190448.50 -0.34
Other Income 2427.50 2710.70 -10.45 2427.50 2710.70 -10.45 11226.50 9847.20 14.01
PBIDT 13286.90 18955.20 -29.90 13286.90 18955.20 -29.90 55890.40 67631.60 -17.36
Interest 56.80 58.80 -3.40 56.80 58.80 -3.40 193.00 151.10 27.73
PBDT 13230.10 18896.40 -29.99 13230.10 18896.40 -29.99 53253.70 70427.10 -24.38
Depreciation 1693.90 1456.90 16.27 1693.90 1456.90 16.27 6894.30 5738.90 20.13
PBT 11536.20 17439.50 -33.85 11536.20 17439.50 -33.85 46359.40 64688.20 -28.33
TAX 2914.60 4408.20 -33.88 2914.60 4408.20 -33.88 11207.60 13111.70 -14.52
Deferred Tax -164.30 -152.20 7.95 -164.30 -152.20 7.95 188.60 -491.50 -138.37
PAT 8621.60 13031.30 -33.84 8621.60 13031.30 -33.84 35151.80 51576.50 -31.85
Equity 1615.70 1615.50 0.01 1615.70 1615.50 0.01 1615.60 1615.20 0.02
PBIDTM(%) 26.17 37.56 -30.34 26.17 37.56 -30.34 29.45 35.51 -17.08

Cipla Share Price

1427.50 33.75 (2.42%)
24-Jul-2026 11:39 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1945.00
Dr. Reddys Labs. 1151.35
Cipla 1427.50
Lupin 2361.85
Zydus Lifesciences 1108.40
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: